Learn about a therapy designed for highly demanding oncological scenarios, combining heterologous NK cells with dual immune checkpoint blockade to expand options for advanced, refractory tumors and those with marked immune evasion.
Therapeutic benefits of NK Heterologous Blockade Cells.
- Therapeutic value
NK Heterologous Blockade Cells therapy offers specialists a treatment designed to enhance the immune response, overcome tumor immune evasion mechanisms, and expand alternatives for highly complex neoplasms.
Key product benefits:
- Heterologous NK cells.
- PD-1 and CTLA-4 blockade.
- Utility in highly complex cases.
- Greater therapeutic potency.
- Clear technical information.
- Medical support.
NK Heterologous Blockade Cells therapy combines tumor recognition, cytotoxic activity, and checkpoint inhibition to provide a stronger alternative for advanced or refractory neoplasms.
Its heterologous profile and dual blockade with nivolumab and ipilimumab expand therapeutic options for patients with immunosuppression, immune evasion, and greater oncological complexity.
Incorporate a therapy with cells from healthy donors, in vitro expansion, and dual immune checkpoint blockade, designed to provide clinical differentiation for highly demanding oncology patients.
- Why choose Gencell Oncology?
Clinical benefits that support your therapeutic decision.
Gencell Oncology develops therapies with autologous Natural Killer cells, allogeneic Natural Killer cells, and dual blockade strategies for physicians who require innovative alternatives in resistant tumors, immunosuppressed patients, and neoplasms with immune evasion mechanisms.
- Request specialized information
Learn about a NK Heterologous Blockade Cells therapy designed to expand options in highly complex oncology.
Obtain technical information about heterologous dual checkpoint blockade NK therapy and discover how this therapy can provide greater immunological potency, clinical differentiation, and strategic value in highly demanding oncological scenarios.